Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis
about
T Cell Migration in Rheumatoid ArthritisOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionUse of natalizumab in multiple sclerosis: current perspectives.Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affinity: a possible mechanism for cell de-adhesion.Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion.Why integrin as a primary target for imaging and therapy.Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injury.The meninges: new therapeutic targets for multiple sclerosis.Fibronectin-α4β1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway.The integrins.Antibody therapeutics: isotype and glycoform selection.Advancement of therapies for neuroprotection in multiple sclerosis.Current concepts and advances in the application of tissue engineering in otorhinolaryngology and head and neck surgery.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.Construction and Characterization of Recombinant HEK Cell Over Expressing α4 Integrin.Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment.Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
P2860
Q26797338-9B073A6C-31DA-480B-87F0-29038A7A6ED8Q26822611-463B9895-09C2-403D-A44F-A70A19D0A17AQ31114633-203C4128-CE4B-4DA7-8823-B283CAD267B3Q33340853-2580EB0B-D1B3-4943-9848-E1D0E8012460Q33903491-61287CDC-890E-46C9-85E8-2A86649DEF19Q34912582-A7C11524-1DF0-4BA2-94C4-B336DCBF69AAQ35167030-818B7947-ED23-434D-9E69-E146CE863F72Q35584727-614D3052-EBA0-4E2A-BC67-052B0023BE39Q36282336-C27A5C81-26D9-4A69-8D1F-FA05E588D20AQ36837362-0D5B5A99-759D-4AEC-BB77-BF8733FFECC2Q36922260-4B8EA73F-D87E-4067-AF0A-E3940F073D1EQ37256701-37429DF2-0730-4078-8327-043BDCDBE25AQ38065427-9A5BEC8B-E744-4611-AA3A-57854E4B92C5Q38172961-45DB05D4-63D0-45A0-A366-524172116E29Q38796218-E5372185-E2A6-48D7-AFC3-635DDFD4B27DQ38837294-089DEDAD-F96E-4782-A1EF-F1FF7724EF43Q40077487-8288A30B-0910-4622-B83C-D677CE233CC9Q42012819-DDE3F580-5631-491B-91A0-88C4A79D8081Q43532290-B2D70E7B-7885-4F0D-9BE2-72A5529A1563Q43937807-8781DAB4-25C3-42A8-8EF2-9D79F422C5D4Q45731720-229F701B-13E9-41CE-89F4-5D4BC15C8594Q50504258-5EDFBCC1-A3FB-428F-A80C-D03FD6961B38
P2860
Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Natalizumab and the role of al ...... reatment of multiple sclerosis
@ast
Natalizumab and the role of al ...... reatment of multiple sclerosis
@en
Natalizumab and the role of al ...... reatment of multiple sclerosis
@nl
type
label
Natalizumab and the role of al ...... reatment of multiple sclerosis
@ast
Natalizumab and the role of al ...... reatment of multiple sclerosis
@en
Natalizumab and the role of al ...... reatment of multiple sclerosis
@nl
prefLabel
Natalizumab and the role of al ...... reatment of multiple sclerosis
@ast
Natalizumab and the role of al ...... reatment of multiple sclerosis
@en
Natalizumab and the role of al ...... reatment of multiple sclerosis
@nl
P2860
P356
P1476
Natalizumab and the role of al ...... reatment of multiple sclerosis
@en
P2093
Paul O'Connor
P2860
P304
P356
10.1517/14712598.7.1.123
P407
P577
2007-01-01T00:00:00Z